帕博利珠单抗阻断PD-1治疗经典型或地方性卡波西肉瘤:一项多中心、单臂、2期研究
这项在法国3家医院开展的多中心、单臂、概念验证2期试验纳入17例需全身治疗的经典型或地方性卡波西肉瘤成人患者,接受帕博利珠单抗200 mg静脉给药每3周一次、持续6个月(8个周期)。6个月内最佳总缓解率为71%(95%CI 44-90),达到预设主要终点;治疗相关不良事件见于13/17例(76%),无严重不良事件或治疗相关死亡。
要点
- 17例可评估患者6个月内最佳总缓解率为71%(95%CI 44-90),超过预设30%的阈值。
- 2例(12%)完全缓解、10例(59%)部分缓解、5例(29%)疾病稳定。
- 治疗相关不良事件13/17例(76%),包括2例3级事件,无治疗相关死亡。
核心结论
- 帕博利珠单抗在经典型和地方性卡波西肉瘤中显示出有前景的抗肿瘤活性,安全性可接受。
- 作者认为若该结果得到进一步研究支持,抗PD-1治疗可能成为经典型和地方性卡波西肉瘤患者的治疗手段之一。
研究设计与样本
- 多中心、单臂、概念验证、2期试验,在法国3家医院开展。
- 纳入年龄18岁及以上、组织学证实为经典型或地方性卡波西肉瘤、伴进展性皮肤扩展需全身治疗、ECOG体能状态评分0-1分的成人患者。
- 治疗方案为帕博利珠单抗200 mg静脉给药每3周一次,持续6个月(8个周期)或直至出现严重毒性。
- 主要终点为6个月时间窗内的最佳总缓解率,按研究者采用改良AIDS临床试验组(ACTG)标准评估的完全缓解或部分缓解判定。
- 采用Simon两阶段最优设计,假设30%缓解率为理想值,17例患者中需至少3例缓解方可达主要终点;最终分析按意向治疗原则纳入全部患者。
主要发现
- 2018年7月2日至2019年12月16日共筛选30例,入组17例,其中经典型8例(47%)、地方性9例(53%)。
- 中位随访20.4个月(IQR 18.1-24.1)。
- 6个月治疗时间窗内最佳缓解:完全缓解2例(12%)、部分缓解10例(59%)、疾病稳定5例(29%),最佳总缓解率71%(95%CI 44-90),达到预设主要终点(即超过30%的缓解率)。
- 治疗相关不良事件发生于13/17例(76%),包括2例3级不良事件:急性心功能失代偿1例(6%)和肉芽肿性反应1例(6%)。
- 2例(12%)因3级急性可逆性心功能失代偿和2级胰腺炎提前终止治疗;另1例出现纵隔淋巴结3级肉芽肿性反应,需类固醇和甲氨蝶呤治疗。
关键数值与推荐
- 主要终点达标条件:17例患者中至少3例缓解,假设理想缓解率为30%。
- 实际最佳总缓解率71%(95%CI 44-90),超过30%的预设阈值。
- 帕博利珠单抗剂量为200 mg静脉给药每3周一次,持续6个月(8个周期)。
临床怎么用
- 原文结论提出,若该结果得到进一步研究支持,抗PD-1治疗可能成为经典型和地方性卡波西肉瘤患者的治疗手段之一(作者认为)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the treatment of iatrogenic and HIV-related Kaposi sarcoma is well defined and mostly based on restoring immune function, the treatment of classic and endemic Kaposi sarcoma is less well established. Chemotherapy or interferon α is used for patients with extensive cutaneous or visceral Kaposi sarcoma, but tolerance might be poor and long-term remission is rare. We aimed to evaluate the activity of pembrolizumab in classic and endemic Kaposi sarcoma with cutaneous extension requiring systemic treatment. METHODS: We did a multicentre, single-arm, proof-of-concept, phase 2 trial in adults aged 18 years or older with histologically proven classic or endemic Kaposi's sarcoma with progressive cutaneous extension requiring systemic treatment and an Eastern Cooperative Oncology Group performance status of 0-1 in three hospitals in France. The patients were treated with 200 mg pembrolizumab intravenously every 3 weeks for 6 months (eight cycles) or until severe toxicity. The primary endpoint was the best overall response rate within the 6-month timeframe, defined by the occurrence of a complete response or partial response and assessed by an investigator using the modified AIDS Clinical Trial Group (ACTG) criteria. Three or more responses among a total 17 patients were needed for the primary endpoint to be met, using a Simon's two-stage optimal design assuming a 30% response rate as desirable. For this final study analysis, all patients were included following the intention-to-treat principle. This study is registered with ClinicalTrials.gov, NCT03469804, and is closed to new participants. FINDINGS: 30 patients were screened for eligibility and 17 patients (eight [47%] with classic and nine [53%] with endemic Kaposi's sarcoma) were enrolled between July 2, 2018, and Dec 16, 2019. The median follow-up was 20·4 months (IQR 18·1-24·1). Two (12%) patients had a complete response, ten (59%) had a partial response, and five (29%) had stable disease as the best response within the 6-month treatment timeframe, with a best overall response rate of 71% (95% CI 44-90), meeting the predefined primary outcome (ie, exceeding a response rate of 30%). Treatment-related adverse events occurred in 13 (76%) of 17 patients, including two grade 3 adverse events (one [6%] acute cardiac decompensation and one [6%] granulomatous reaction). Treatment was prematurely discontinued in two (12%) patients due to grade 3 acute reversible cardiac decompensation and grade 2 pancreatitis, and one other patient had a grade 3 granulomatous reaction in mediastinal lymph nodes requiring steroids and methotrexate treatment. There were no serious adverse events or treatment-related deaths. INTERPRETATION: In this prospective trial, which to our knowledge is the first to assess the role of PD-1 blockade in patients with classic and endemic Kaposi's sarcoma, pembrolizumab showed promising anti-tumour activity with an acceptable safety profile. If this result is supported by further studies, treatment with anti-PD-1 could be part of the therapeutic armamentarium for patients with classic and endemic Kaposi's sarcoma. FUNDING: MSD France.
引用
- Delyon J, Biard L, Renaud M, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2022. PMID: 35279271. doi:10.1016/S1470-2045(22)00097-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。